Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 2394Neoplasms 1813Carcinoma, Non-Small-Cell Lung 1596Prostatic Neoplasms 1296Colorectal Neoplasms 1138Lung Neoplasms 981Neoplasm Metastasis 830Multiple Myeloma 791Leukemia, Myeloid, Acute 767Ovarian Neoplasms 674Pancreatic Neoplasms 661Melanoma 659Squamous Cell Carcinoma of Head and Neck 584Carcinoma, Hepatocellular 566Recurrence 562Brain Neoplasms 526Glioblastoma 512Head and Neck Neoplasms 500Stomach Neoplasms 497Triple Negative Breast Neoplasms 464Lymphoma 453Uterine Cervical Neoplasms 449Carcinoma, Renal Cell 423Precursor Cell Lymphoblastic Leukemia-Lymphoma 410Lymphoma, Non-Hodgkin 388Endometrial Neoplasms 381Sarcoma 368Lymphoma, Follicular 356Urinary Bladder Neoplasms 354Hematologic Neoplasms 351

Interventions

Nivolumab 2pembrolizumab 1folfirinox 1durvalumab 1Trastuzumab 1Single Person 1Paclitaxel 1Irinotecan 1IFL protocol 1Folfox protocol 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Gastroesophageal Adenocarcinoma × 1 year × Clear all
NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

University of California, Irvine

Phase 1 Recruiting
20 enrolled
Gastrointestinal

Gastroesophageal Adenocarcinoma

NCT04021108 2025-06-24

Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)

Weill Medical College of Cornell University

Phase 2 Active not recruiting
80 enrolled
Gastrointestinal

Gastroesophageal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡